December 28, 2020 09:16 AM EST
R&D

Af­ter a ‘break­through’ be­gin­ning to 2020, lit­tle Aprea gets crushed by a PhI­II fail­ure

John Carroll

Editor & Founder

Boston-based biotech Aprea Ther­a­peu­tics $APRE start­ed the year with a promis­ing break­through ther­a­py des­ig­na­tion from the FDA for its lead p53 re­ac­ti­vat­ing pro­gram for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times